Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 76Nivolumab 63Ipilimumab 40Specimen Handling 32Magnetic Resonance Spectroscopy 27Cyclophosphamide 25Biopsy 19cemiplimab 16Radiosurgery 14relatlimab 13fludarabine 13CTLA-4 Antigen 13trametinib 11binimetinib 11Opdualag 11fludarabine phosphate 10avelumab 9Immunoglobulin G 9Blood Specimen Collection 9lifileucel 8dabrafenib 8atezolizumab 8Radiotherapy 8Disulfides 8encorafenib 7aldesleukin 7X-Rays 7Paclitaxel 7Standard of Care 6Interleukin-2 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
famitinib × Dermatologic × 90 days × Clear all
NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡